New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

While peanut allergy therapies from Aimmune and DBV Technologies are locked in a race to the finish line, influential cost-effectiveness watchdog ICER has determined that neither therapy offers superior net health benefit compared to strict peanut avoidance, in a final report published on Wednesday.